DDInter119 DDInter1070
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
Linagliptin {u} (Compound) resembles {v} (Compound) Alogliptin
Linagliptin {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Linagliptin {u} (Compound) binds {v} (Gene) CYP3A4
Linagliptin {u} (Compound) is included by {v} (Pharmacologic Class) Dipeptidyl Peptidase 4 Inhibitors
Linagliptin {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Linagliptin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Linagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Linagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metamfetamine
Linagliptin {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Linagliptin (Compound) resembles Alogliptin (Compound)
Linagliptin (Compound) treats type 2 diabetes mellitus (Disease)
Linagliptin (Compound) binds CYP3A4 (Gene)
Linagliptin (Compound) is included by Dipeptidyl Peptidase 4 Inhibitors (Pharmacologic Class)
Linagliptin (Compound) causes Upper respiratory tract infection (Side Effect)
Linagliptin may cause a minor interaction that can limit clinical effects when taken with Amcinonide
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine
Linagliptin may lead to a major life threatening interaction when taken with Bexarotene